Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Human Genetic Therapies Boosts Shire, Thanks To Replagal Growth

This article was originally published in The Pink Sheet Daily

Executive Summary

Genzyme's inability to provide Fabry disease patients with Fabrazyme has created an opening for Replagal, whose half-year sales are up 77 percent year-over-year.

You may also be interested in...



Shire's Strong 2010 Performance Helped By Huge Sales Growth In HGT Business

Continuing to capitalize on supply problems plaguing rival Genzyme, Shire reported 81% year-over-year sales growth for Fabry disease drug Replagal.

Shire's Strong 2010 Performance Helped By Huge Sales Growth In HGT Business

Continuing to capitalize on supply problems plaguing rival Genzyme, Shire reported 81% year-over-year sales growth for Fabry disease drug Replagal.

Shire Emphasizes The GI Space In Its Bid For Movetis

Only five years ago, Shire's specialty pharma business consisted of one product, Adderall XR, one market, the U.S., and one patient type - children. Multiple generics companies had filed ANDAs, however, and the company was looking to broaden its base

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071128

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel